Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.

Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS.

JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.

PMID:
29800971
2.

Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.

Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS.

Cancer Med. 2018 May 17. doi: 10.1002/cam4.1558. [Epub ahead of print]

3.

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer.

Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM Jr, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB.

Cancer Discov. 2018 Apr;8(4):417-427. doi: 10.1158/2159-8290.CD-17-1227. Epub 2018 Feb 5.

PMID:
29431697
4.

Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.

Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx031.

PMID:
28954285
5.

Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529.

Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, Allen JN, Kwak EL, Murphy JE, Clark JW, Ryan DP, Cusack JC, Bordeianou LG, Berger DL, Wo JY.

Adv Radiat Oncol. 2017 Feb 6;2(2):110-117. doi: 10.1016/j.adro.2017.01.009. eCollection 2017 Apr-Jun.

6.

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.

Juric D, de Bono JS, LoRusso PM, Nemunaitis J, Heath EI, Kwak EL, Macarulla Mercadé T, Geuna E, Jose de Miguel-Luken M, Patel C, Kuida K, Sankoh S, Westin EH, Zohren F, Shou Y, Tabernero J.

Clin Cancer Res. 2017 Sep 1;23(17):5015-5023. doi: 10.1158/1078-0432.CCR-16-2888. Epub 2017 May 10.

7.

Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.

Wo JY, Niemierko A, Ryan DP, Blaszkowsky LS, Clark JW, Kwak EL, Lillemoe KD, Drapek LN, Zhu AX, Allen JN, Faris JE, Murphy JE, Nipp R, Fernandez-Del Castillo C, Ferrone CR, Hong TS.

Am J Clin Oncol. 2018 Jul;41(7):656-661. doi: 10.1097/COC.0000000000000349.

PMID:
28134673
8.

Case 35-2016. A 62-Year-Old Man with Dysphagia.

Kwak EL, Hong TS, Forcione DG, Kambadakone A, Lennerz JK.

N Engl J Med. 2016 Nov 17;375(20):1983-1991. No abstract available.

PMID:
27959609
9.

Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.

Keane FK, Wo JY, Ferrone CR, Clark JW, Blaszkowsky LS, Allen JN, Kwak EL, Ryan DP, Lillemoe KD, Fernandez-Del Castillo C, Hong TS.

Am J Clin Oncol. 2018 Jun;41(6):607-612. doi: 10.1097/COC.0000000000000336.

PMID:
27740973
10.

What's the Best Way to Treat GE Junction Tumors? Approach Like Gastric Cancer.

Mullen JT, Kwak EL, Hong TS.

Ann Surg Oncol. 2016 Nov;23(12):3780-3785. Epub 2016 Jul 26. Review.

PMID:
27459983
11.

A protein and mRNA expression-based classification of gastric cancer.

Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A, Lennerz JK, Hong TS, Kwak EL, Lauwers GY.

Mod Pathol. 2016 Jul;29(7):772-84. doi: 10.1038/modpathol.2016.55. Epub 2016 Apr 1.

12.

The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality.

Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, Mullen JT.

J Surg Oncol. 2016 Apr;113(5):560-4. doi: 10.1002/jso.24179. Epub 2016 Jan 21.

PMID:
26792144
13.

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX.

J Clin Oncol. 2016 Feb 10;34(5):460-8. doi: 10.1200/JCO.2015.64.2710. Epub 2015 Dec 14.

14.

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.

Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate AJ, Bardelli A, Corcoran RB.

Cancer Discov. 2016 Feb;6(2):147-153. doi: 10.1158/2159-8290.CD-15-1283. Epub 2015 Dec 7.

15.

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.

Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, Jessop NA, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB.

Cancer Discov. 2015 Dec;5(12):1271-81. doi: 10.1158/2159-8290.CD-15-0748. Epub 2015 Oct 2. Erratum in: Cancer Discov. 2016 Dec;6(12 ):1402.

16.

Familial Gastric Cancers.

Setia N, Clark JW, Duda DG, Hong TS, Kwak EL, Mullen JT, Lauwers GY.

Oncologist. 2015 Dec;20(12):1365-77. doi: 10.1634/theoncologist.2015-0205. Epub 2015 Sep 30. Review.

17.

Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach.

Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, Mullen JT.

J Gastrointest Surg. 2016 Jan;20(1):172-9; discussion 179. doi: 10.1007/s11605-015-2954-5. Epub 2015 Sep 22.

PMID:
26394879
18.

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S.

J Clin Oncol. 2015 Dec 1;33(34):4023-31. doi: 10.1200/JCO.2015.63.2471. Epub 2015 Sep 21.

19.

Predictors of Lymph Node Metastasis in Western Early Gastric Cancer.

Ahmad R, Setia N, Schmidt BH, Hong TS, Wo JY, Kwak EL, Rattner DW, Lauwers GY, Mullen JT.

J Gastrointest Surg. 2016 Mar;20(3):531-8. doi: 10.1007/s11605-015-2945-6. Epub 2015 Sep 18.

PMID:
26385006
20.

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.

Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX.

Oncologist. 2015 Sep;20(9):1019-27. doi: 10.1634/theoncologist.2015-0210. Epub 2015 Aug 5.

21.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G.

N Engl J Med. 2015 Jul 30;373(5):428-37. doi: 10.1056/NEJMoa1411366.

22.

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.

Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM Jr, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB.

Cancer Discov. 2015 Apr;5(4):358-67. doi: 10.1158/2159-8290.CD-14-1518. Epub 2015 Feb 11.

23.

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell J, Spicer J, Kwak EL, Pandya SS, Millham R, Borzillo G, Pierce KJ, Han L, Houk BE, Gallo JD, Alsina M, Braña I, Tabernero J.

Clin Cancer Res. 2015 Apr 15;21(8):1888-95. doi: 10.1158/1078-0432.CCR-14-1306. Epub 2015 Feb 4.

24.

Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.

Chan E, Kwak EL, Hwang J, Heiskala M, de La Bourdonnaye G, Mita M.

Cancer Chemother Pharmacol. 2015 Apr;75(4):701-9. doi: 10.1007/s00280-015-2682-2. Epub 2015 Jan 28.

PMID:
25627002
25.

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C.

Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.

26.

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.

Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ.

Int J Cancer. 2015 Apr 15;136(8):1967-75. doi: 10.1002/ijc.29225. Epub 2014 Sep 29.

27.

Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control.

Wo JY, Childs SK, Szymonifka J, Mamon HJ, Ryan DP, Blaszkowsky LS, Kwak EL, Ferrone CR, Allen JN, Zhu AX, Wolpin BM, Chan JA, Abrams TA, McCleary NJ, Fernandez-Del Castillo C, Hong TS.

Pract Radiat Oncol. 2014 Mar-Apr;4(2):e117-e123. doi: 10.1016/j.prro.2013.07.006. Epub 2013 Aug 9.

PMID:
24890357
28.

A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.

Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):830-8. doi: 10.1016/j.ijrobp.2014.03.034. Epub 2014 May 24.

29.

Adjuvant therapy for gastric cancers: more answers or more questions?

Hong TS, Kwak EL.

Ann Surg Oncol. 2014 Oct;21(11):3367-8. doi: 10.1245/s10434-014-3778-3. Epub 2014 May 20. No abstract available.

PMID:
24841350
30.

The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation.

Schoenfeld JD, Wo JY, Mamon HJ, Kwak EL, Mullen JT, Enzinger PZ, Blaskowsky LS, Ryan DP, Hong TS.

Am J Clin Oncol. 2016 Jun;39(3):243-7. doi: 10.1097/COC.0000000000000047.

PMID:
24577163
31.

Mutational analysis and clinical correlation of metastatic colorectal cancer.

Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS.

Cancer. 2014 May 15;120(10):1482-90. doi: 10.1002/cncr.28599. Epub 2014 Feb 5.

32.

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.

Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX.

Clin Cancer Res. 2014 Apr 1;20(7):1884-90. doi: 10.1158/1078-0432.CCR-13-2649. Epub 2014 Jan 29.

33.

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer.

Blaszkowsky LS, Ryan DP, Szymonifka J, Borger DR, Zhu AX, Clark JW, Kwak EL, Mamon HJ, Allen JN, Vasudev E, Shellito PC, Cusack JC, Berger DL, Hong TS.

Ann Oncol. 2014 Jan;25(1):121-6. doi: 10.1093/annonc/mdt516.

34.

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, Krygowski M, Liang Y, Turnbull KW, Shapiro GI, Soria JC.

J Clin Oncol. 2014 Jan 10;32(2):68-75. doi: 10.1200/JCO.2012.47.2787. Epub 2013 Dec 9.

PMID:
24323026
35.

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.

Ghamande S, Lin CC, Cho DC, Shapiro GI, Kwak EL, Silverman MH, Tseng Y, Kuo MW, Mach WB, Hsu SC, Coleman T, Yang JC, Cheng AL, Ghalib MH, Chuadhary I, Goel S.

Invest New Drugs. 2014 Jun;32(3):445-51. doi: 10.1007/s10637-013-0044-7. Epub 2013 Nov 24.

PMID:
24271274
36.

Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer.

Wo JY, Mamon HJ, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Tseng YD, Napolitano BN, Ancukiewicz M, Swanson RS, Lillemoe KD, Fernandez-del Castillo C, Hong TS.

Radiother Oncol. 2014 Jan;110(1):160-4. doi: 10.1016/j.radonc.2013.10.027. Epub 2013 Nov 11.

PMID:
24231241
37.

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.

Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Braña I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C, Edelman G.

Clin Cancer Res. 2014 Jan 1;20(1):233-45. doi: 10.1158/1078-0432.CCR-13-1777. Epub 2013 Oct 28. Erratum in: Clin Cancer Res. 2015 May 1;21(9):2192.

38.

Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.

Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, Hong TS.

J Gastrointest Cancer. 2014 Mar;45(1):34-9. doi: 10.1007/s12029-013-9546-y.

39.

Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010.

Cai S, Hong TS, Goldberg SI, Fernandez-del Castillo C, Thayer SP, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Willett CG, Lillemoe KD, Warshaw AL, Wo JY.

Cancer. 2013 Dec 1;119(23):4196-204. doi: 10.1002/cncr.28329. Epub 2013 Sep 4.

40.

Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.

Kwak EL, Shapiro GI, Cohen SM, Becerra CR, Lenz HJ, Cheng WF, Su WC, Robohn M, Le Maulf F, Lobmeyer MT, Chand VK, Iafrate AJ.

Cancer. 2013 Aug 15;119(16):3043-51. doi: 10.1002/cncr.28120. Epub 2013 Jun 14.

41.

Noncurative gastrectomy for gastric adenocarcinoma should only be performed in highly selected patients.

Schmidt B, Look-Hong N, Maduekwe UN, Chang K, Hong TS, Kwak EL, Lauwers GY, Rattner DW, Mullen JT, Yoon SS.

Ann Surg Oncol. 2013 Oct;20(11):3512-8. doi: 10.1245/s10434-013-3024-4. Epub 2013 Jun 14.

PMID:
23765416
42.

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS.

Oncologist. 2013;18(5):543-8. doi: 10.1634/theoncologist.2012-0435. Epub 2013 May 8.

43.

Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.

Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS.

Oncologist. 2013;18(4):377-8. doi: 10.1634/theoncologist.2012-0378. Epub 2013 Apr 11.

44.

Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.

Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch MT, Lanuti M, Rattner DW, Fuchs CS, Enzinger PC.

Oncologist. 2013;18(3):281-7. doi: 10.1634/theoncologist.2012-0208. Epub 2013 Feb 21.

45.

Targeted inhibition in tumors with ALK dependency.

Kwak EL, Clark JW, Shaw AT.

Lung Cancer (Auckl). 2013 Jan 9;4:1-8. doi: 10.2147/LCTT.S16313. eCollection 2013. Review.

46.

Targeted therapies with chemoradiation in esophageal cancer: development and future directions.

Hong TS, Wo JY, Kwak EL.

Semin Radiat Oncol. 2013 Jan;23(1):31-7. doi: 10.1016/j.semradonc.2012.09.004. Review.

PMID:
23207045
47.

Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?

Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V, Hong TS, Kwak EL, Lauwers GY, Ryan DP, Wargo JA, Lillemoe KD, Ferrone CR.

Ann Surg. 2013 Apr;257(4):731-6. doi: 10.1097/SLA.0b013e318263da2f.

PMID:
22968073
48.

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT.

Lancet Oncol. 2012 Oct;13(10):1011-9. doi: 10.1016/S1470-2045(12)70344-3. Epub 2012 Sep 4.

49.

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.

Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ.

J Clin Oncol. 2012 Jul 1;30(19):2348-53. doi: 10.1200/JCO.2011.36.8282. Epub 2012 Apr 23.

50.

Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.

Arvold ND, Willett CG, Fernandez-del Castillo C, Ryan DP, Ferrone CR, Clark JW, Blaszkowsky LS, Deshpande V, Niemierko A, Allen JN, Kwak EL, Wadlow RC, Zhu AX, Warshaw AL, Hong TS.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e337-43. doi: 10.1016/j.ijrobp.2011.12.068. Epub 2012 Mar 11.

PMID:
22414286

Supplemental Content

Support Center